Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17021
Country/Region: South Africa
Year: 2016
Main Partner: Right to Care
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $15,295,364 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,573,323
Care: TB/HIV (HVTB) $2,015,286
Care: Pediatric Care and Support (PDCS) $485,750
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $971,500
Treatment: Adult Treatment (HTXS) $8,763,755
Treatment: Pediatric Treatment (PDTX) $485,750
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV_DSD Age/Sex: 10-14 Female 2017 68
GEND_GBV_DSD Age/Sex: 15-19 Female 2017 100
GEND_GBV_DSD Age/Sex: 20-24 Female 2017 104
GEND_GBV_DSD By PEP service provision (related to sexual violence services provided) 2017 126
GEND_GBV_DSD By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 136
GEND_GBV_DSD By type of service: Sexual Violence (Post-Rape Care) 2017 136
GEND_GBV_DSD Number of people receiving post-GBV care 2017 272
GEND_GBV_DSD Sum of Age/Sex Disaggregates 2017 68
HTC_TST_DSD Age/sex: 1-9 2017 682
HTC_TST_DSD Age/sex: 10-14 Female 2017 598
HTC_TST_DSD Age/sex: 10-14 Male 2017 170
HTC_TST_DSD Age/sex: 15-19 Female 2017 3,667
HTC_TST_DSD Age/sex: 15-19 Male 2017 654
HTC_TST_DSD Age/sex: 20-24 Female 2017 5,619
HTC_TST_DSD Age/sex: 20-24 Male 2017 4,286
HTC_TST_DSD Age/sex: 25-49 Female 2017 5,035
HTC_TST_DSD Age/sex: 25-49 Male 2017 10,238
HTC_TST_DSD Age/sex: 50+ Female 2017 1,007
HTC_TST_DSD Age/sex: 50+ Male 2017 654
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 15,328
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 15,832
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 939
HTC_TST_DSD Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 511
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 32,610
HTC_TST_DSD Service Delivery Point (Community): Mobile testing 2017 14,977
HTC_TST_DSD Service Delivery Point (Facility): Other PITC 2017 15,870
HTC_TST_DSD Service Delivery Point (Facility): PMTCT 2017 1,763
HTC_TST_DSD Sum of Age/Sex disaggregates 2017 31,928
HTC_TST_DSD Sum of Aggregated Age/Sex 15+ 2017 31,160
HTC_TST_DSD Sum of Aggregated Age/Sex <15 2017 1,450
HTC_TST_DSD Sum of Aggregated Age/Sex disaggregates 2017 32,610
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Female 2017 49
HTC_TST_DSD Test Result by Age and Sex: Positive: 10-14 Male 2017 6
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Female 2017 426
HTC_TST_DSD Test Result by Age and Sex: Positive: 15-19 Male 2017 108
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Female 2017 741
HTC_TST_DSD Test Result by Age and Sex: Positive: 20-24 Male 2017 555
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Female 2017 803
HTC_TST_DSD Test Result by Age and Sex: Positive: 25-49 Male 2017 1,235
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Female 2017 160
HTC_TST_DSD Test Result by Age and Sex: Positive: 50+ Male 2017 108
HTC_TST_DSD Test Result by Age: Positive: 1-9 2017 24
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,131
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,005
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Female 2017 61
HTC_TST_DSD Test Result by Aggregated Age and Sex: Positive <15 Male 2017 18
HTC_TST_TA Age/sex: 1-9 2017 2,315
HTC_TST_TA Age/sex: 10-14 Female 2017 580
HTC_TST_TA Age/sex: 10-14 Male 2017 580
HTC_TST_TA Age/sex: 15-19 Female 2017 3,421
HTC_TST_TA Age/sex: 15-19 Male 2017 2,221
HTC_TST_TA Age/sex: 20-24 Female 2017 10,258
HTC_TST_TA Age/sex: 20-24 Male 2017 6,666
HTC_TST_TA Age/sex: 25-49 Female 2017 17,090
HTC_TST_TA Age/sex: 25-49 Male 2017 11,107
HTC_TST_TA Age/sex: 50+ Female 2017 3,421
HTC_TST_TA Age/sex: 50+ Male 2017 2,221
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 208,194
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 135,266
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 10,579
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 10,573
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 364,612
HTC_TST_TA Service Delivery Point (Facility): Other PITC 2017 328,155
HTC_TST_TA Service Delivery Point (Facility): PMTCT 2017 36,457
HTC_TST_TA Sum of Age/Sex disaggregates 2017 57,565
HTC_TST_TA Sum of Aggregated Age/Sex 15+ 2017 343,460
HTC_TST_TA Sum of Aggregated Age/Sex <15 2017 21,152
HTC_TST_TA Sum of Aggregated Age/Sex disaggregates 2017 364,612
HTC_TST_TA Test Result by Age and Sex: Positive: 10-14 Female 2017 21
HTC_TST_TA Test Result by Age and Sex: Positive: 10-14 Male 2017 21
HTC_TST_TA Test Result by Age and Sex: Positive: 15-19 Female 2017 545
HTC_TST_TA Test Result by Age and Sex: Positive: 15-19 Male 2017 364
HTC_TST_TA Test Result by Age and Sex: Positive: 20-24 Female 2017 1,636
HTC_TST_TA Test Result by Age and Sex: Positive: 20-24 Male 2017 1,094
HTC_TST_TA Test Result by Age and Sex: Positive: 25-49 Female 2017 2,727
HTC_TST_TA Test Result by Age and Sex: Positive: 25-49 Male 2017 1,826
HTC_TST_TA Test Result by Age and Sex: Positive: 50+ Female 2017 545
HTC_TST_TA Test Result by Age and Sex: Positive: 50+ Male 2017 364
HTC_TST_TA Test Result by Age: Positive: 1-9 2017 79
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 33,185
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 22,246
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Female 2017 368
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Male 2017 368
PMTCT_ART_TA Already on ART at beginning of current pregnancy 2017 1,774
PMTCT_ART_TA New on ART 2017 15,952
PMTCT_ART_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 63,975
PMTCT_EID_TA By infants who received a virologic test within 2 months of birth 2017 17,749
PMTCT_EID_TA Number of infants with a positive virological test result within 2 months of birth 2017 267
PMTCT_EID_TA Sum of Infant Age disaggregates 2017 17,749
PMTCT_STAT_TA By Age (DREAMS SNUs ONLY): 15-19 2017 1,730
PMTCT_STAT_TA By Age (DREAMS SNUs ONLY): 20-24 2017 3,461
PMTCT_STAT_TA By Age (DREAMS SNUs ONLY): 25-49 2017 12,107
PMTCT_STAT_TA By: Known positives at entry 2017 5,325
PMTCT_STAT_TA By: Number of new positives identified 2017 12,401
PMTCT_STAT_TA Number of new ANC and L&D clients 2017 64,994
PMTCT_STAT_TA Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 63,975
PMTCT_STAT_TA Required only for DREAMS countries - By known positives: 15-19 2017 519
PMTCT_STAT_TA Required only for DREAMS countries - By known positives: 20-24 2017 1,040
PMTCT_STAT_TA Required only for DREAMS countries - By known positives: 25-49 2017 3,635
PMTCT_STAT_TA Required only for DREAMS countries - By new positives: 15-19 2017 1,212
PMTCT_STAT_TA Required only for DREAMS countries - By new positives: 20-24 2017 2,422
PMTCT_STAT_TA Required only for DREAMS countries - By new positives: 25-49 2017 8,493
PMTCT_STAT_TA Required only for DREAMS countries - Denominator: 15-19 2017 1,739
PMTCT_STAT_TA Required only for DREAMS countries - Denominator: 20-24 2017 3,473
PMTCT_STAT_TA Required only for DREAMS countries - Denominator: 25-49 2017 12,162
PMTCT_STAT_TA Sum of Positives Status disaggregates 2017 17,726
PP_PREV_TA Aggregated Age/sex: 15+ Female 2017 12,583
PP_PREV_TA Aggregated Age/sex: <15 Female 2017 854
PP_PREV_TA Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 13,437
PP_PREV_TA Total number of people in the target population 2017 120,155
TB_ART_TA Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 4,028
TB_ART_TA Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 218
TB_ART_TA Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,745
TB_ART_TA Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 218
TB_ART_TA The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 8,002
TB_ART_TA The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 7,209
TB_SCREENDX_TA Screen Results: Screened Positive for TB 2017 35,232
TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Female 2017 197,244
TB_SCREENDX_TA Screened for TB by Age/Sex: 15+ Male 2017 133,854
TB_SCREENDX_TA Screened for TB by Age/Sex: <15 Female 2017 10,564
TB_SCREENDX_TA Screened for TB by Age/Sex: <15 Male 2017 10,564
TB_SCREENDX_TA The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 352,226
TB_SCREENDX_TA [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 31,727
TB_SCREENDX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 3,179
TB_SCREENDX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 1,586
TB_SCREENDX_TA [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 26,962
TB_STAT_TA Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7,015
TB_STAT_TA Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 375
TB_STAT_TA Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,752
TB_STAT_TA Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 375
TB_STAT_TA Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 12,517
TB_STAT_TA Total number of registered new and relapsed TB cases, during the reporting period 2017 13,128
TX_CURR_DSD Aggregated Age/Sex: 15+ Female 2017 7,658
TX_CURR_DSD Aggregated Age/Sex: 15+ Male 2017 5,106
TX_CURR_DSD Aggregated Age/Sex: <15 Female 2017 393
TX_CURR_DSD Aggregated Age/Sex: <15 Male 2017 393
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2017 13,550
TX_CURR_DSD Sum of Aggregated Age/Sex 15+ 2017 12,764
TX_CURR_DSD Sum of Aggregated Age/Sex <15 2017 786
TX_CURR_DSD Sum of Aggregated Age/Sex disaggregates 2017 13,550
TX_CURR_TA Aggregated Age/Sex: 15+ Female 2017 203,138
TX_CURR_TA Aggregated Age/Sex: 15+ Male 2017 135,415
TX_CURR_TA Aggregated Age/Sex: <15 Female 2017 10,420
TX_CURR_TA Aggregated Age/Sex: <15 Male 2017 10,420
TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART) 2017 359,393
TX_CURR_TA Sum of Aggregated Age/Sex 15+ 2017 338,553
TX_CURR_TA Sum of Aggregated Age/Sex <15 2017 20,840
TX_CURR_TA Sum of Aggregated Age/Sex disaggregates 2017 359,393
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Female 2017 2,059
TX_NEW_DSD Aggregated Grouping by Age/Sex: 15+ Male 2017 1,373
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Female 2017 90
TX_NEW_DSD Aggregated Grouping by Age/Sex: <15 Male 2017 90
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 3,612
TX_NEW_DSD Sum of Aggregated Age/Sex disaggregates 2017 3,612
TX_NEW_TA Aggregated Grouping by Age/Sex: 15+ Female 2017 53,577
TX_NEW_TA Aggregated Grouping by Age/Sex: 15+ Male 2017 35,724
TX_NEW_TA Aggregated Grouping by Age/Sex: <15 Female 2017 2,347
TX_NEW_TA Aggregated Grouping by Age/Sex: <15 Male 2017 2,347
TX_NEW_TA Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 93,995
TX_NEW_TA Sum of Aggregated Age/Sex disaggregates 2017 93,995
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Female 2017 6,892
TX_PVLS_DSD Denominator Aggregated Age/Sex: 15+ Male 2017 4,595
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Female 2017 354
TX_PVLS_DSD Denominator Aggregated Age/Sex: <15 Male 2017 354
TX_PVLS_DSD Denominator: Indication: Routine 2017 11,585
TX_PVLS_DSD Denominator: Indication: Targeted 2017 610
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 12,195
TX_PVLS_DSD Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 10,975
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Female 2017 6,204
TX_PVLS_DSD Numerator Aggregated Age/Sex: 15+ Male 2017 4,135
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Female 2017 318
TX_PVLS_DSD Numerator Aggregated Age/Sex: <15 Male 2017 318
TX_PVLS_DSD Numerator: Indication: Routine 2017 10,426
TX_PVLS_DSD Numerator: Indication: Targeted 2017 549
TX_PVLS_TA Denominator Aggregated Age/Sex: 15+ Female 2017 182,812
TX_PVLS_TA Denominator Aggregated Age/Sex: 15+ Male 2017 121,881
TX_PVLS_TA Denominator Aggregated Age/Sex: <15 Female 2017 9,381
TX_PVLS_TA Denominator Aggregated Age/Sex: <15 Male 2017 9,381
TX_PVLS_TA Denominator: Indication: Routine 2017 307,281
TX_PVLS_TA Denominator: Indication: Targeted 2017 16,173
TX_PVLS_TA Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 323,455
TX_PVLS_TA Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 291,109
TX_PVLS_TA Numerator Aggregated Age/Sex: 15+ Female 2017 164,543
TX_PVLS_TA Numerator Aggregated Age/Sex: 15+ Male 2017 109,684
TX_PVLS_TA Numerator Aggregated Age/Sex: <15 Female 2017 8,441
TX_PVLS_TA Numerator Aggregated Age/Sex: <15 Male 2017 8,441
TX_PVLS_TA Numerator: Indication: Routine 2017 276,555
TX_PVLS_TA Numerator: Indication: Targeted 2017 14,554
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,933
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,696
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,622
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,465
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 202
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 190
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 202
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 190
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 6,541
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,959
TX_RET_TA Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 136,526
TX_RET_TA Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 128,345
TX_RET_TA Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 91,015
TX_RET_TA Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 85,560
TX_RET_TA Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,003
TX_RET_TA Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,579
TX_RET_TA Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,003
TX_RET_TA Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,579
TX_RET_TA Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 227,063
TX_RET_TA Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 241,547
Cross Cutting Budget Categories and Known Amounts Total: $709,360
Gender: Gender Based Violence (GBV) $300,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Motor Vehicles: Leased $109,360
Gender: Gender Equality $300,000
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation